Amphastar Pharmaceuticals (AMPH) Work In Process (2015 - 2026)

Amphastar Pharmaceuticals' Work In Process history runs 12 years deep, the most recent figure standing at $42.6 million for Q1 2026.

• On a quarterly basis, Work In Process fell 2.6% year-over-year to $42.6 million in Q1 2026; TTM through Mar 2026 was $42.6 million, a 2.6% decrease from a year earlier, with the FY2025 full-year figure at $40.4 million, up 23.27% from the prior year.
• Work In Process improved to $42.6 million in Q1 2026 per AMPH's latest filing, from $40.4 million in the prior quarter.
• Across five years, Work In Process topped out at $43.8 million in Q1 2025 and bottomed at $28.3 million in Q3 2023.
• The 5-year median for Work In Process is $38.6 million (2024), against an average of $37.1 million.
• Across the five-year window, Work In Process fell 26.63% in 2023 and soared 31.34% in 2025, its largest moves.
• Year by year, Work In Process stood at $37.1 million in 2022, then declined by 16.9% to $30.8 million in 2023, then climbed by 6.44% to $32.8 million in 2024, then rose by 23.27% to $40.4 million in 2025, then climbed by 5.44% to $42.6 million in 2026.
• Per Business Quant, the three latest AMPH Work In Process figures stand at $42.6 million (Q1 2026), $40.4 million (Q4 2025), and $42.5 million (Q3 2025).